Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the composition, activation, and regulation of the JAK/STAT pathway and highlights its role and inhibitors in various diseases, but reports no new experimental results.

JAK inhibitors may reduce depression risk in alopecia areata patients.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

In this study, treatment with oral JAK inhibitors was associated with improved disease outcomes in 80.6% of patients with refractory lichen planopilaris over a mean duration of 5 months.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

This review discusses the use of follicular unit extraction and scalp micropigmentation in treating male pattern baldness, noting that scalp micropigmentation provides a non-surgical option to emulate natural hair appearance without downtime.

This study found that baricitinib significantly reduced alopecia severity in JAK inhibitor-naïve patients compared to those previously treated with tofacitinib, indicating that switching JAK inhibitors can be safe and may be beneficial for selected patients with partial prior responses.

The book is a detailed guide for plastic surgeons with clear explanations and is recommended for both new and experienced practitioners.

This review summarizes existing evidence on the efficacy and safety of JAK inhibitors for treating alopecia areata and emphasizes the need for improved topical formulations.

This review discusses the use of Janus kinase inhibitors for alopecia areata and reports promising short-term efficacy but low-quality evidence, highlighting the need for further research to confirm long-term safety and effectiveness.

This study evaluated eight JAK inhibitor regimens for alopecia areata and provided high-quality evidence on their comparative effectiveness, which can aid clinicians in decision-making and inform medical practice guidelines.

This review discusses how JAK inhibitors, like tofacitinib and baricitinib, show promise in improving conditions like lichen planopilaris and frontal fibrosing alopecia by reducing severity scores and enhancing hair regrowth, though further research on safety and personalized approaches is needed.

This retrospective cohort study found no significant association between Janus kinase inhibitors and increased malignancy risk in alopecia areata patients, but traditional immunosuppressants were linked to higher risks of internal and hematologic malignancies.

Infections and missed treatments trigger flares in alopecia areata patients on JAK inhibitors.

JAK inhibitors help regrow eyebrow and eyelash hair and improve anxiety and depression in some alopecia areata patients.

This systematic review reported that while combining low-dose oral minoxidil with Janus kinase inhibitors may enhance treatment outcomes in alopecia areata, the evidence remains weak due to limited sample sizes and potential publication bias, and more rigorous trials are necessary to assess efficacy and safety.

This literature review found that Janus kinase inhibitors may help achieve remission in patients with refractory primary neutrophilic cicatricial alopecias, though data is limited to small case series and reports.

This review suggests that oral Janus kinase inhibitors like tofacitinib, ruxolitinib, and baricitinib show promise for treating alopecia areata in adults, both in terms of efficacy and safety.

This source presents an expert consensus framework for determining which Australian patients with alopecia areata should receive subsidized JAK inhibitor therapy, emphasizing the need for future research including patient perspectives to enhance criteria, ensure fair treatment access, and evaluate real-world outcomes.

This case report observed successful hair regrowth with ritlecitinib in a patient with severe alopecia who did not respond to a previous year of baricitinib therapy.

This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.

This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.

This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.

This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.

This source reports that tofacitinib and ruxolitinib showed potential efficacy and acceptable safety profiles in treating various autoimmune disorders, including alopecia areata and psoriasis, based on a review of clinical studies, while recommending physicians consider the individual risks and benefits.

Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.

This article discusses barriers to obtaining JAK inhibitor therapy for patients with alopecia areata and highlights that racial inequities may worsen these difficulties; it calls for further advocacy to improve access.

This study suggests that Janus kinase inhibitors may offer a potential treatment option for refractory lichen planopilaris and frontal fibrosing alopecia, showing positive response rates between 42% and 100%, though evidence quality is low.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.